Theriva Biologics公司宣布,其候选药物VCN-01与度伐利尤单抗联合疗法,在治疗难治性头颈部鳞状细胞癌患者的一项研究中,观察到了总生存期的显著延长。这一积极数据为针对这一侵袭性癌症开发新的治疗选择带来了希望。
Theriva Biologics公司宣布,其候选药物VCN-01与度伐利尤单抗联合疗法,在治疗难治性头颈部鳞状细胞癌患者的一项研究中,观察到了总生存期的显著延长。这一积极数据为针对这一侵袭性癌症开发新的治疗选择带来了希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.